Teijin and Aska Pharmaceutical to co-develop gynaecological drugs

Core Insights - Teijin Pharma has entered a joint research agreement with Aska Pharmaceutical to develop small-molecule drug candidates targeting gynaecological diseases, leveraging Teijin's expertise in computer-aided drug design and AI [1][2] - The collaboration aims to identify "hit" compounds that interact with specific molecular targets, followed by optimization to ensure efficacy, pharmacokinetic properties, and safety for drug development [2][3] - Aska Pharmaceutical contributes clinical expertise in women's health, focusing on unmet medical needs, which complements Teijin's advanced drug discovery technologies [3][4] Company Strategies - Teijin Pharma is enhancing its drug candidate discovery process through improved simulation accuracy and predictive modeling, which shortens timelines and increases the probability of success in drug development [2] - Aska Pharmaceutical specializes in urology, internal medicine, and obstetrics and gynaecology, with a portfolio aimed at supporting women at various life stages [4] - The partnership aims to provide innovative treatments to improve the quality of life for women suffering from gynaecological conditions [4] Recent Developments - Teijin has submitted an application to Japan's Pharmaceuticals and Medical Devices Agency for manufacturing and marketing approval of lonapegsomatropin, a prodrug of somatropin, which is administered once weekly [5]